QUOTE AND NEWS
StreetInsider.com  5 hrs ago  Comment 
Net Element, Inc. (Nasdaq: NETE) 44.8% HIGHER; regaining composure following a 16.3 percent dip on Thursday. Shares are trading strong back over the $4 level. Conversant, Inc. (Nasdaq: CNVR) 30.0% HIGHER; Alliance Data Systems and Conversant...
TheStreet.com  6 hrs ago  Comment 
NEW YORK (TheStreet) -- Shares ofaAmarina plunged 23.76% to $1.38 Friday after the company announced that the FDA denied its appeal to reinstate Special Protocol Assessment status on a phase IIIastudy of the company'saprescription fish-oil pill...
FiercePharma  7 hrs ago  Comment 
Amarin and its omega-3 pill have struck out with the FDA again. The Irish company said today that the agency has again turned down its appeal to reconsider its clinical data it hoped would help it win a label extension for Vascepa, dealing a new...
SeekingAlpha  7 hrs ago  Comment 
By The Specialist: This morning's Amarin (NASDAQ:AMRN) press release states, "The U.S. Food and Drug Administration (FDA) has denied Amarin's appeal of FDA's rescission of the ANCHOR clinical trial Special Protocol Assessment (NYSE:SPA)...
Motley Fool  7 hrs ago  Comment 
Amarin's stock is plunging today. Here's why.
Benzinga  8 hrs ago  Comment 
Amarin Corporation plc (NASDAQ: AMRN) shares tumbled 20.44% to $1.44 following an update on ANCHOR trial SPA deal rescission appeal. Ku6 Media Co (NASDAQ: KUTV) fell 12.69% to $1.23 after the company reported a Q2 loss of $0.11 per share on...
SeekingAlpha  Sep 11  Comment 
By Curve Tech Investing: 1) Introduction Recently, Amarin Corporation (NASDAQ:AMRN) has regained some ground after large share price losses associated with FDA actions. The current bull thesis can be found in these two accounts of the company's...
SeekingAlpha  Aug 11  Comment 
ByScrying Biotech: I don't always like the decisions my editors at Seeking Alpha make. And I'm sure they don't care. John Thero doesn't like the decision to postpone ANCHOR approval that the FDA made. And I'm sure they don't care. Because FDA...
SeekingAlpha  Aug 10  Comment 
ByIAEResearch: Amarin (NASDAQ:AMRN) reported second quarter results on August 7, 2014 and the company has made considerable progress in a number of areas. The company reported basic EPS of $0.09 and diluted EPS of $0.08. However, for the six-month...
SeekingAlpha  Aug 9  Comment 
Amarin Corporation PLC (AMR) Q2 2014 Earnings Conference Call August 07, 2014 04:30 a.m. ET Executives Michael James Farrell – Principal Financial Officer, Principal Accounting Officer and Controller John F. Thero – Chief...





 



References

This is a test No its not

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki